Major Healthcare Milestone: Advanced Proton Treatment Technology Arrives in Seoul with Multi-Million Euro Investment

NftDeepBreather · 2025-12-31T15:28:07+00:00

Ion Beam Applications has partnered with Seoul St. Mary's Hospital to deploy its Proteus PLUS proton therapy system, enhancing cancer treatment in the Asia-Pacific region. The project involves a significant investment for a new eight-floor facility, targeting patient admissions by 2029, and aims to improve treatment precision and capacity.

NftDeepBreather

2025-12-31 15:28:07

Abstract generation in progress

Ion Beam Applications SA (IBAB.BR, IOBCF) has secured a significant partnership with Seoul St. Mary’s Hospital, operated by the Catholic University of Korea, marking an important expansion of cutting-edge cancer treatment capabilities in the Asia-Pacific region. The Belgian medical technology firm will deploy its Proteus PLUS proton therapy system equipped with ion beam precision technology to transform Seoul’s oncology landscape.

Contract Scope and Financial Impact

The deployment represents a substantial investment, with the three-room Proteus PLUS configuration—including comprehensive multi-year maintenance services—typically valued between 80 million and 100 million euros. This contract reflects growing global demand for advanced radiation therapy solutions that leverage ion beam technology for enhanced treatment precision.

Facility Development and Timeline

The newly constructed proton therapy center will become a comprehensive medical facility spanning eight floors across both surface and underground levels, encompassing 37,851 square meters. Seoul St. Mary’s Hospital has established an ambitious operational timeline, targeting patient admissions by the end of 2029. This timeframe encompasses installation, commissioning, and regulatory compliance procedures.

Advanced Treatment Capabilities

The integrated system will feature three gantry-equipped treatment rooms, enabling simultaneous operation and expanded patient throughput. Notably, once regulatory authorities grant approval, the facility will incorporate DynamicARC beam delivery technology, enhancing the precision of ion-based therapeutic interventions and expanding treatment options for complex oncological cases.

Market Context

On the Brussels Stock Exchange, Ion Beam Applications closed trading Wednesday at EUR 12.14 per share, reflecting investor confidence in the company’s international expansion strategy. This Seoul installation underscores the accelerating adoption of ion beam proton therapy solutions across Asia’s leading medical institutions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.